NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“NuCana’s priorities are to define the next stage of clinical development for NUC-7738 in melanoma following the anticipated December announcement of the Phase 2 NuTide:701 expansion study results and latest translational data.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“Recruitment is complete in our Phase 2 expansion cohort of NuTide:701, evaluating NUC-7738 in combination with Keytruda® (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We plan to present these results and the latest translational data at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026, taking place December 14-16 in London.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“Following clearance of our Investigational New Drug application (“IND”) earlier this year, we are continuing our dialogue with the U.S. Food and Drug Administration (the “FDA”) regarding a potential registrational strategy for NUC-7738 in melanoma.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“The grant of a European composition-of-matter patent for NUC-7738 further strengthens our intellectual property position, building on similar patents in the United States and China.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We believe we have established a clear development pathway for NUC-3373 through an extensive AI-enabled analysis of proprietary data from more than 800 cancer cell lines alongside large public datasets.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We believe this work has further characterized NUC-3373’s mechanism of action and differentiation from 5-fluorouracil (5-FU), supporting its greater anti-cancer activity in preclinical models compared with 5-FU and enabling us to prioritize tumor types, identify potential biomarkers of sensitivity and select rational combination strategies for further evaluation.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“The next phase of testing is now under way in cancer cell lines and our in-house patient-derived organoid models, which is intended to validate these findings and help guide the selection of potential future clinical development opportunities.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“This work gives us a focused basis for advancing NUC-3373 in settings where its differentiated biology may offer the greatest potential to benefit patients.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“With cash resources anticipated to fund our planned operations into 2029, we are focused on delivering the NUC-7738 Phase 2 expansion results, defining its potential registrational strategy and advancing the preclinical validation of NUC-3373.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We are excited by the opportunities ahead and look forward to updating shareholders on these priorities.”